Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment
This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...